Marizyme, Inc. (MRZM)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 457.7 Thousand USD | -314.06% |
| 2022 | 179.16 Thousand USD | 37.9% |
| 2021 | 129.92 Thousand USD | -6.42% |
| 2020 | 138.84 Thousand USD | 0.0% |
| 2019 | - USD | -100.0% |
| 2018 | 113.00 USD | -99.21% |
| 2017 | 14.26 Thousand USD | -82.76% |
| 2016 | 82.74 Thousand USD | -53.35% |
| 2015 | 177.36 Thousand USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | -100.0% |
| 2012 | 11.45 Million USD | -15.9% |
| 2011 | 13.62 Million USD | 141162.13% |
| 2010 | 9645.00 USD | -69.57% |
| 2009 | 31.69 Thousand USD | 1057.91% |
| 2008 | 2737.00 USD | 153.59% |
| 2007 | -5107.00 USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -222.56 Thousand USD | -19.61% |
| 2024 Q1 | -186.07 Thousand USD | -72.35% |
| 2023 Q2 | 135.12 Thousand USD | 50.65% |
| 2023 Q3 | 130.54 Thousand USD | -3.39% |
| 2023 Q4 | -107.96 Thousand USD | -182.7% |
| 2023 Q1 | 89.69 Thousand USD | 32.16% |
| 2023 FY | -383.51 Thousand USD | -314.06% |
| 2022 FY | 179.16 Thousand USD | 37.9% |
| 2022 Q2 | 50.78 Thousand USD | 124.14% |
| 2022 Q1 | -210.36 Thousand USD | -40.49% |
| 2022 Q3 | 60.5 Thousand USD | 19.15% |
| 2022 Q4 | 67.87 Thousand USD | 12.17% |
| 2021 Q4 | -149.73 Thousand USD | -893.99% |
| 2021 FY | 129.92 Thousand USD | -6.42% |
| 2021 Q1 | 43.11 Thousand USD | 8.94% |
| 2021 Q2 | 41.56 Thousand USD | -3.59% |
| 2021 Q3 | 18.85 Thousand USD | -54.63% |
| 2020 Q1 | -471.37 Thousand USD | 0.0% |
| 2020 Q4 | 39.57 Thousand USD | -60.14% |
| 2020 Q3 | 99.27 Thousand USD | 0.0% |
| 2020 Q2 | - USD | 100.0% |
| 2020 FY | 138.84 Thousand USD | 0.0% |
| 2019 FY | - USD | -100.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q1 | - USD | 100.0% |
| 2019 Q2 | -237.36 Thousand USD | 0.0% |
| 2019 Q3 | - USD | 100.0% |
| 2018 Q3 | - USD | 100.0% |
| 2018 Q1 | 5553.00 USD | 124.36% |
| 2018 FY | 113.00 USD | -99.21% |
| 2018 Q4 | -3001.00 USD | 0.0% |
| 2018 Q2 | -2441.00 USD | -143.96% |
| 2017 FY | 14.26 Thousand USD | -82.76% |
| 2017 Q3 | 19.08 Thousand USD | 5919.82% |
| 2017 Q4 | -22.79 Thousand USD | -219.42% |
| 2017 Q2 | -328.00 USD | -103.65% |
| 2017 Q1 | 8988.00 USD | -94.01% |
| 2016 FY | 82.74 Thousand USD | -53.35% |
| 2016 Q4 | 150 Thousand USD | 475.0% |
| 2016 Q1 | -30 Thousand USD | 0.0% |
| 2016 Q3 | -40 Thousand USD | 0.0% |
| 2016 Q2 | - USD | 100.0% |
| 2015 FY | 177.36 Thousand USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2013 Q3 | 2.79 Million USD | -7.14% |
| 2013 Q2 | 3 Million USD | 41.68% |
| 2013 Q1 | 2.12 Million USD | 22.24% |
| 2013 Q4 | -7.92 Million USD | -383.7% |
| 2013 FY | - USD | -100.0% |
| 2012 Q3 | 3.12 Million USD | -3.45% |
| 2012 FY | 11.45 Million USD | -15.9% |
| 2012 Q4 | 1.73 Million USD | -44.41% |
| 2012 Q2 | 3.23 Million USD | -5.33% |
| 2012 Q1 | 3.41 Million USD | -3.33% |
| 2011 Q2 | 3.08 Million USD | -77.34% |
| 2011 Q1 | 13.62 Million USD | 0.0% |
| 2011 Q3 | 3.85 Million USD | 24.84% |
| 2011 FY | 13.62 Million USD | 141162.13% |
| 2011 Q4 | 3.53 Million USD | -8.26% |
| 2010 Q1 | -1946.00 USD | 0.0% |
| 2010 FY | 9645.00 USD | -69.57% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 100.0% |
| 2009 FY | 31.69 Thousand USD | 1057.91% |
| 2009 Q1 | 29.77 Thousand USD | 1561.66% |
| 2009 Q2 | 3266.00 USD | -89.03% |
| 2009 Q4 | - USD | -100.0% |
| 2009 Q3 | 1021.00 USD | -68.74% |
| 2008 Q4 | 1792.00 USD | 313.08% |
| 2008 FY | 2737.00 USD | 153.59% |
| 2008 Q1 | -3300.00 USD | -181.44% |
| 2008 Q2 | 990.00 USD | 130.0% |
| 2008 Q3 | -841.00 USD | -184.95% |
| 2007 Q4 | 4052.00 USD | 108.33% |
| 2007 Q1 | - USD | 100.0% |
| 2007 FY | -5107.00 USD | 0.0% |
| 2007 Q2 | 40.00 USD | 0.0% |
| 2007 Q3 | 1945.00 USD | 4762.5% |
| 2006 Q4 | -10 Thousand USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 18865.97% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 96.09% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 243.253% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.616% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 101.774% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 1048.428% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 468.369% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 96.948% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -14655.061% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 95.327% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -596.358% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 1440.269% |
| Mesoblast Limited | -35.16 Million USD | 101.301% |
| Genus plc | 178.7 Million USD | 99.744% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.792% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -635.548% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -11.59% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 4260.927% |
| ContraFect Corporation | -154 Thousand USD | 397.209% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 1015.404% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -496.269% |
| IMV Inc. | -962.29 Thousand USD | 147.563% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 218.116% |
| MultiCell Technologies, Inc. | 49.32 USD | -927925.142% |
| ONE Bio Corp. | 20.12 Million USD | 97.726% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 98.863% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -835.996% |
| Q BioMed Inc. | -8988.00 USD | 5192.368% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 98.38% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 3067.466% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 98.968% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 140.094% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -553.86% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 9342.771% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -225.767% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 569.366% |
| GB Sciences, Inc. | -624.00 USD | 73449.679% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 632.038% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.994% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 220149.038% |
| Enzolytics Inc. | 30.7 Thousand USD | -1390.498% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 5.126% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.959% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 188.959% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 25.864% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.888% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 5268.27% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 645.865% |
| Kadimastem Ltd | -630.13 Thousand USD | 172.635% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 53.673% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 95.238% |
| BioStem Technologies, Inc. | 15.42 Million USD | 97.033% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 3967.36% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -159.233% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -159.233% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 66.275% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 1678.283% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -1.702% |
| SYBLEU INC | 11.69 Thousand USD | -3813.321% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 90.067% |
| Bioxytran, Inc. | -8285.00 USD | 5624.466% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 222.708% |
| Neutra Corp. | 14.33 Thousand USD | -3092.899% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 658.173% |
| PureTech Health plc | -1.6 Million USD | 128.553% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 145.714% |
| IXICO plc | 3.27 Million USD | 86.003% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 165.951% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 125.556% |
| CSL Limited | 7.7 Billion USD | 99.994% |
| Cellectis S.A. | 18 Thousand USD | -2442.789% |